. Author manuscript; available in PMC: 2017 Jun 12.

Published in final edited form as: Bone Marrow Transplant. 2016 Dec 12;52(3):400–408. doi: 10.1038/bmt.2016.265

Table 4b.

Summary of studies analyzing risk factors for chronic GVHD after UCBT

Study	Population	Incidence of chronic GVHD	Risk Factors
Macmillan et al.¹¹	Single UCBT (n=80)	18%	Prior grades II–IV acute GVHD
Macmillan et al.¹¹	Double UCBT (n=185)	17%	Prior grades II–IV acute GVHD
Lazaryan et al.¹⁰	Single UCBT (n=295)	7%	Age ≥ 18 Non-use of cyclosporine/MMF for GVHD prophylaxis
Lazaryan et al.¹⁰	Double UCBT (n=416)	26%	Higher HLA-mismatch Myeloablative conditioning Prior grades II–IV acute GVHD
Ponce et al.¹³	Double UCBT (n=115)	23%	Not reported
Narimatsu et al.¹⁴	Single UCBT (n=1072)	28%	Higher recipient body weight Higher HLA-mismatch Myeloablative conditioning Use of mycophenolate mofetil Prior grades II–IV acute GVHD
Xavier et al.¹²	Double UCBT (n=921)	25%	Higher HLA-mismatch Prior grades II–IV acute GVHD
Chen et al.	Single UCBT (n=810)	27%	Prior grades II–IV acute GVHD
Chen et al.	Double UCBT (n=594)	26%	Prior grades II–IV acute GVHD

Abbreviations: GVHD = graft-vs.-host disease; UCBT = umbilical cord blood transplantation; UCB = umbilical cord blood; MMF = mycophenolate mofetil; ATG = anti-thymocyte globulin; HLA = human leukocyte antigen; iv-TCD = in vivo T-cell depletion